Skip to main content
. 2011 Dec 13;106(2):333–343. doi: 10.1038/bjc.2011.546

Figure 2.

Figure 2

Indole-3-carbinol and bortezomib combination sensitises ovarian cancer cells to platinum-based chemotherapeutic agents. (A) OVCAR3 and OVCAR5 cells were treated with I3C, bortezomib, cisplatin or (C) carboplatin at the indicated concentrations for 48 h. Cell viability was measured as described in Materials and Methods. The data shown represent the mean±s.e.m. (n=3). (B) SKOV3, OVCAR8, HEY and CAOV3 cells were treated with I3C, bortezomib and cisplatin as in (A). The data shown represent the mean±s.e.m. (n=3).